Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai discusses Chimeric Antigen Receptor T-Cells from ASH 2015
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content